INBX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Inhibrx Biosciences Inc (INBX) is not a strong buy at the moment for a beginner investor with a long-term focus. Despite bullish technical indicators and a positive analyst rating, the lack of recent news catalysts, poor financial performance, and no significant trading trends suggest holding off on investment until more favorable conditions arise.
The technical indicators for INBX are bullish. The MACD is positive and contracting, indicating upward momentum. The RSI is at 80.109, suggesting the stock is overbought. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 83.043 and R2: 89.089, while support levels are at S1: 63.474 and S2: 57.428.
Analyst Dara Azar from Stifel initiated coverage with a Buy rating and a $150 price target, citing advancements in clinical programs and potential for INBRX-106 to enhance Keytruda's efficacy.
The company's financial performance in Q4 2025 showed a 100% YoY revenue drop, a significant net income loss of -$32.83M (down 31.4% YoY), and a declining EPS of -2.11 (down 31.72% YoY). Additionally, there is no recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q4 2025, the company reported a 100% YoY revenue drop to $0, a net income loss of -$32.83M (down 31.4% YoY), and an EPS decline to -2.11 (down 31.72% YoY). Gross margin remained at 100%.
Stifel analyst Dara Azar initiated coverage with a Buy rating and a $150 price target, citing advancements in clinical programs and potential for INBRX-106 to enhance Keytruda's efficacy.
